Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3204374 | 0.82 | CNR2 (0.38) | CNR2SMN1; SMN2PARP1ACACB | |
| SCHEMBL3548339 | 0.73 | CNR2 (0.33) | CNR2SMN1; SMN2PARP1 | |
| SCHEMBL18048258 | 0.71 | L3MBTL1 (0.42) | ALDH1A1SMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL3209466 | 0.71 | L3MBTL1 (0.43) | ALDH1A1L3MBTL1 | |
| SCHEMBL13223504 | 0.66 | SMN1; SMN2 (0.38) | CNR2SMN1; SMN2PARP1 | |
| SCHEMBL16598705 | 0.63 | F2RL1 (0.43) | CNR2SMN1; SMN2PARP1 | |
| SCHEMBL13495539 | 0.63 | ACACB (0.30) | ACACB | |
| SCHEMBL17162718 | 0.63 | SMN1; SMN2 (0.39) | ALDH1A1CNR2SMN1; SMN2PARP1 | |
| SCHEMBL1632308 | 0.63 | SMN1; SMN2 (0.39) | ALDH1A1CNR2SMN1; SMN2PARP1 | |
| SCHEMBL16614728 | 0.61 | F2RL1 (0.52) | ALDH1A1CNR2SMN1; SMN2PARP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010019930-A1 | UREA DERIVATIVES AS INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | MAP4K2, MAP3K1, MAP3K20 | ALDH1A1 3577/4885CNR2 4569/4885SMN1; SMN2 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.